# A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

> **NCT04814368** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 23 (actual)

## Conditions studied

- Knee Osteoarthritis

## Interventions

- **BIOLOGICAL:** canakinumab
- **BIOLOGICAL:** LNA043
- **OTHER:** Placebo to canakinumab

## Key facts

- **NCT ID:** NCT04814368
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-27
- **Primary completion:** 2024-06-24
- **Final completion:** 2024-06-24
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04814368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04814368, "A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04814368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*